Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 TrialDaiichi Sankyo2025-04-04 08:37:19ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine TherapyDaiichi Sankyo2025-03-06 15:57:51ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic
-
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2025-01-31 15:16:20Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated
-
Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and lack of awareness of the disease still prevailDaiichi Sankyo2026-03-17 08:18:04Survey reveals: 88% of Western Europeans would like better information on breast cancer, misconceptions and
-
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily WithdrawnDaiichi Sankyo2024-12-24 08:26:44Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast CancerDaiichi Sankyo2024-03-25 10:05:10Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small
-
VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo2023-11-09 08:10:56VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed
-
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung CancerDaiichi Sankyo2023-10-23 08:14:19ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced
-
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo2023-09-15 16:13:51Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML
-
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung CancerDaiichi Sankyo2023-09-15 16:11:35ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung
